USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
MIRNA THERAPEUTICS, INC.
Address:
2150 WOODWARD ST
AUSTIN, TX 78744-
Phone:
N/A
URL:
N/A
EIN:
126182480
DUNS:
805509424
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,341,762.00 5

Award List:

Combination molecular therapeutics for lung cancer

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$171,527.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Lung cancer is the leading cause of cancer deaths in the United States with an estimated gt160,000 deaths and gt200,000 newly diagnosed cases each year. Despite the use of surgery, chemotherapy and radiation in the trea tment of lung cancer, the survival rate for… More

MicroRNA therapeutics for prostate cancer

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$282,967.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Prostate cancer (PrCa) is the most commonly diagnosed cancer in men and the second leading cause of cancer deaths in males, following only lung cancer. Despite advances leading to more efficient detection, a small but s ignificant number of patients present with… More

Development of modified microRNA therapeutics

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$287,270.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Experimental evidence accumulated in the past few years indicates that several miRNAs likely function as tumor suppressors and that the altered expression of these miRNAs likely contributes to a significant number of hu man cancers. Mirna Therapeutics has… More

Systemic delivery of chitosan/miRNA nanoparticles to prostate tumors

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$299,999.00
Agency:
HHS
Principal Investigator:
Andreas G. Bader – 512-681-5367
Abstract:
DESCRIPTION (provided by applicant): MicroRNAs (miRNAs) have emerged as a promising new class of therapeutics for cancer. miRNAs are small, non-coding RNAs that determine cell fate by post-transcriptionally regulating the expression of a broad but nevertheless specific set of genes. miRNAs can… More

Therapeutic miRNAs in combination with conventional chemotherapy

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$299,999.00
Agency:
HHS
Principal Investigator:
Andreas G. Bader – 512-681-5367
Abstract:
DESCRIPTION (provided by applicant): Mirna Therapeutics, a Texas-based company, is developing non-small cell lung cancer (NSCLC) therapies using tumor suppressor miRNAs. This approach, miRNA replacement therapy , is based on the concept that re-introduction of miRNAs depleted in cancer cells… More